ImmuNext, J&J deal

ImmuNext granted Johnson & Johnson's Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize products that antagonize the V-region immunoglobulin-containing suppressor of T cell activation (VISTA). J&J plans to develop immunotherapies for cancer. ImmuNext will receive an upfront payment, plus milestones, which could total more than $150 million. ImmuNext is also eligible for tiered royalties. Janssen will provide funding for ImmuNext to conduct basic research around the target and pathway. ...